EP3854402A1 — Treatment or prevention of transplant rejection
Assigned to CTI Biopharma Corp · Expires 2021-07-28 · 5y expired
What this patent protects
The present invention provides the use of protein kinase inhibitors, in particular JAK2 inhibitors of formula (I), as set forth in the specification, in the prevention or treatment of cell transplant rejection and graft versus host disease (GvHD). Also provided are combination th…
USPTO Abstract
The present invention provides the use of protein kinase inhibitors, in particular JAK2 inhibitors of formula (I), as set forth in the specification, in the prevention or treatment of cell transplant rejection and graft versus host disease (GvHD). Also provided are combination therapies for the prevention or treatment of cell transplant rejection and graft versus host disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.